NUK - logo
E-resources
Peer reviewed Open access
  • A feasibility study of lapa...
    Hyung, Woo Jin; Yang, Han-Kwang; Han, Sang-Uk; Lee, Young-Jun; Park, Joong-Min; Kim, Jin Jo; Kwon, Oh Kyung; Kong, Seong Ho; Kim, Hyoung-Il; Lee, Hyuk-Joon; Kim, Wook; Ryu, Seung Wan; Jin, Sung-Ho; Oh, Sung Jin; Ryu, Keun Won; Kim, Min-Chan; Ahn, Hye-Seong; Park, Young Kyu; Kim, Young-Ho; Hwang, Sun-Hwi; Kim, Jong Won; Cho, Gyu Seok

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 01/2019, Volume: 22, Issue: 1
    Journal Article

    Background With improved short-term surgical outcomes, laparoscopic distal gastrectomy has rapidly gained popularity. However, the safety and feasibility of laparoscopic total gastrectomy (LTG) has not yet been proven due to the difficulty of the technique. This single-arm prospective multi-center study was conducted to evaluate the use of LTG for clinical stage I gastric cancer. Methods Between October 2012 and January 2014, 170 patients with pathologically proven, clinical stage I gastric adenocarcinoma located at the proximal stomach were enrolled. Twenty-two experienced surgeons from 19 institutions participated in this clinical trial. The primary end point was the incidence of postoperative morbidity and mortality at postoperative 30 days. The severity of postoperative complications was categorized according to Clavien–Dindo classification, and the incidence of postoperative morbidity and mortality was compared with that in a historical control. Results Of the enrolled patients, 160 met criteria for inclusion in the full analysis set. Postoperative morbidity and mortality rates reached 20.6% (33/160) and 0.6% (1/160), respectively. Fifteen patients (9.4%) had grade III or higher complications, and three reoperations (1.9%) were performed. The incidence of morbidity after LTG in this trial did not significantly differ from that reported in a previous study for open total gastrectomy (18%). Conclusions LTG performed by experienced surgeons showed acceptable postoperative morbidity and mortality for patients with clinical stage I gastric cancer.